Hikma Expectations Stabilize – But Generics Still Set To Take A Hit
Firm Cites ‘Strong Momentum’ For Injectables And Branded Divisions
After multiple cuts to its Generics guidance earlier this year, Hikma has reiterated its expectations for the company’s full-year results, citing momentum for the firm’s Injectables and Branded segments as well as promising that growth is on the horizon for Generics in 2023.
